Five million children die before their fifth birthday every year; more than 250 million cases of malaria, tuberculosis, and HIV lead to 2.8 million deaths; and 1 in every 4 children grow up malnourished. Today’s most exciting advances in biotechnology hold enormous potential to help tackle these major global health challenges.
We invest in new frontiers of science to address global health challenges through paradigm-shifting drugs, vaccines, biologics, and gene therapies. We support the development of critical assets and platform technologies that facilitate the discovery, manufacturing, and delivery of more effective, lower-cost vaccines, therapeutics, and diagnostics. These include novel technologies in vaccine and drug development and delivery, alternative biologics, in vivo cell therapy and gene editing, low-cost point-of-care diagnostics, and food and microbial therapeutics.
News & stories
Developing monoclonal antibodies for global health
How can we use long-term partnership to translate promising new technologies into global health products?
